Dataset Information


MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.

ABSTRACT: Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic multimodality. Gemcitabine is the effective first-line drug in pancreatic adenocarcinoma treatment. However, gemcitabine chemoresistance of pancreatic adenocarcinoma cells has been a major obstacle for limiting its treatment effect. Our study found that p70S6K1 plays an important role in gemcitabine chemoresistence. MiR-145 is a tumor suppressor which directly targets p70S6K1 for inhibiting its expression in pancreatic adenocarcinoma, providing new therapeutic scheme. Our findings revealed a new mechanism underlying gemcitabine chemoresistance in pancreatic adenocarcinoma cells.


PROVIDER: S-EPMC5342594 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2008-01-01 | S-EPMC2652398 | BioStudies
1000-01-01 | S-EPMC5746084 | BioStudies
2015-01-01 | S-EPMC4692438 | BioStudies
2019-01-01 | S-EPMC6481023 | BioStudies
2008-01-01 | S-EPMC4514112 | BioStudies
2015-01-01 | S-EPMC4452412 | BioStudies
2020-01-01 | S-EPMC7505810 | BioStudies
2020-01-01 | S-EPMC7156657 | BioStudies
2012-01-01 | S-EPMC3500221 | BioStudies
2019-01-01 | S-EPMC6739963 | BioStudies